drugset
drugset / Trial / NCT03792971

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

NCT03792971 ↗

Phase 1 Completed 13 enrolled Galera Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This will be a single center, phase 1, open-label, fixed-sequence study under fasting conditions to evaluate the effect of 90 mg intravenous (IV) infusions of GC4419 on the single-dose pharmacokinetic (PK) of dextromethorphan (DM) capsules liquid filled.

Timeline

Start
2019-02-10
Primary completion
2019-02-15
Completion
2019-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Avasopasem manganese Other / unclassified 90 mg Intravenous
Subject Dextromethorphan Unknown 60 mg —

Indications

No indication recorded.